IMGN - ImmunoGen, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
10.25
+0.28 (+2.81%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close9.97
Open10.00
Bid9.95 x 200
Ask10.89 x 100
Day's range9.95 - 10.37
52-week range4.80 - 13.41
Volume2,763,172
Avg. volume2,743,115
Market cap1.525B
Beta3.59
PE ratio (TTM)N/A
EPS (TTM)-1.08
Earnings date27 Jul 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.50
Trade prices are not sourced from all markets
  • Here's Why ImmunoGen Fell 15.1% in June
    Motley Fool7 days ago

    Here's Why ImmunoGen Fell 15.1% in June

    A secondary offering dilutes investors.

  • Business Wire8 days ago

    ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2018 Operating Results

    ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference call at 8:00 a.m. ET on Friday, July 27, 2018 to discuss its second quarter operating results. The call may also be accessed through the Investors section of the Company’s website, www.immunogen.com. ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.

  • Better Buy: Exelixis, Inc. vs. Immunogen, Inc.
    Motley Fool25 days ago

    Better Buy: Exelixis, Inc. vs. Immunogen, Inc.

    Which of these cancer-focused biotech stocks is the better pick right now?

  • Business Wirelast month

    ImmunoGen Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

    ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 2,055,000 shares of ImmunoGen’s common stock at a price of $11.00 per share, before underwriting discounts. The exercise of the option brings the total shares of common stock to be sold by ImmunoGen in the offering to 15,755,000 shares. All of the shares in the offering are to be sold by ImmunoGen.

  • ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer
    Zackslast month

    ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer

    With ImmunoGen's (IMGN) lead pipeline candidate, mirvetuximab soravtansine getting Fast Track designation in the United States, its development and review are likely to get expedited.

  • Business Wirelast month

    ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer

    ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead program, mirvetuximab soravtansine. The designation is for the treatment of patients with medium to high folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who received at least one, but no more than three prior systemic treatment regimens, and for whom single-agent chemotherapy is appropriate as the next line of therapy. “We are pleased the FDA has granted Fast Track designation for mirvetuximab soravtansine,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer.

  • Business Wirelast month

    ImmunoGen Announces Closing of Public Offering of Common Stock

    ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 13,700,000 shares of its common stock at a price to the public of $11.00 per share. The gross proceeds to ImmunoGen from the offering (before deducting the underwriting discounts and offering expenses) were $150.7 million. In addition, ImmunoGen has granted the underwriters a 30-day option to purchase up to an additional 2,055,000 shares of common stock at the public offering price, less the underwriting discount.

  • Here's Why ImmunoGen Inc. Fell 9.2% Today
    Motley Foollast month

    Here's Why ImmunoGen Inc. Fell 9.2% Today

    A secondary offering will dilute investors.

  • Business Wirelast month

    ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock

    ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an upsized underwritten public offering of 13,700,000 shares of its common stock at a price of $11.00 per share, before underwriting discounts. In addition, ImmunoGen has granted the underwriters a 30-day option to purchase up to an additional 2,055,000 shares of common stock at the public offering price, less the underwriting discount. The offering was upsized from the previously announced offering size of 12,000,000 shares of common stock.

  • Has ImmunoGen Inc (NASDAQ:IMGN) Improved Earnings Growth In Recent Times?
    Simply Wall St.last month

    Has ImmunoGen Inc (NASDAQ:IMGN) Improved Earnings Growth In Recent Times?

    Understanding ImmunoGen Inc’s (NASDAQ:IMGN) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check to gainRead More...

  • MarketWatchlast month

    Immunogen shares down 4% after company's plans for secondary offering

    Shares of Immunogen Inc. fell more than 4% late Tuesday after the biotech company said it plans to offer and sell 12 million shares of its common stock in a public offering. J.P. Morgan Securities, Goldman Sachs, and Cowen and Co. are joint book-runners. Shares of Immunogen ended the regular trading session up 7.4%.

  • Business Wirelast month

    ImmunoGen Announces Proposed Public Offering of Common Stock

    ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, 12,000,000 shares of its common stock in an underwritten public offering. ImmunoGen also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares of common stock to be sold in the offering are to be offered by ImmunoGen.

  • Why Is ImmunoGen (IMGN) Up 4.2% Since Its Last Earnings Report?
    Zacks2 months ago

    Why Is ImmunoGen (IMGN) Up 4.2% Since Its Last Earnings Report?

    ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Why ImmunoGen Jumped Higher Today
    Motley Fool2 months ago

    Why ImmunoGen Jumped Higher Today

    Investors are looking forward to the biotech's presentation at ASCO.

  • Business Wire2 months ago

    ImmunoGen Announces Webcast of Presentation at Jefferies 2018 Global Healthcare Conference

    ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Jefferies 2018 Global Healthcare Conference. ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.

  • Business Wire2 months ago

    ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with Avastin® and Carboplatin in Ovarian Cancer

    ImmunoGen, Inc., , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer today announced positive data from the FORWARD II trial evaluating mirvetuximab soravtansine in multiple combination cohorts in patients with folate receptor alpha -positive ovarian cancer.

  • Business Wire2 months ago

    Synaffix Further Strengthens Its Scientific Advisory Board with the Addition of John Lambert PhD, Former CSO of ImmunoGen

    AMSTERDAM--(BUSINESSWIRE)-- Synaffix B.V. announced today the expansion of its Scientific Advisory Board (SAB) with the addition of Dr. John M. Lambert, the former Chief Scientific Officer of ImmunoGen, ...

  • ImmunoGen Presses Forward
    Motley Fool2 months ago

    ImmunoGen Presses Forward

    The biotech waits for clinical trial results for its lead drug, mirvetuximab.

  • ImmunoGen (IMGN) Q1 Loss Wider Than Expected, Revenues Beat
    Zacks2 months ago

    ImmunoGen (IMGN) Q1 Loss Wider Than Expected, Revenues Beat

    ImmunoGen (IMGN) reports wider-than-expected loss in Q1. Lower license and milestone fees resulted in substantial decrease in year-over-revenues.

  • Associated Press3 months ago

    ImmunoGen: 1Q Earnings Snapshot

    On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 30 cents. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...

  • Business Wire3 months ago

    ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results

    ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today reviewed recent progress in the business and reported operating results for the quarter ended March 31, 2018.

  • Business Wire3 months ago

    ImmunoGen Announces Webcast of Presentation at Deutsche Bank’s 43rd Annual Health Care Conference

    ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company’s lead product candidate, mirvetuximab soravtansine, is in the Phase 3 FORWARD I trial for FRα-positive platinum-resistant ovarian cancer, and is in the Phase 1b/2 FORWARD II trial in combination regimens for earlier-stage disease.

  • What's in Store for ImmunoGen (IMGN) This Earnings Season?
    Zacks3 months ago

    What's in Store for ImmunoGen (IMGN) This Earnings Season?

    ImmunoGen's (IMGN) considerable progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the stock in Q1.

  • Why ImmunoGen, Inc. Stock Is on the Rise Today
    Motley Fool3 months ago

    Why ImmunoGen, Inc. Stock Is on the Rise Today

    ImmunoGen's lead product candidate appears to be on the right track.

  • Business Wire3 months ago

    ImmunoGen Announces Successful Completion of Interim Analysis for FORWARD I Phase 3 Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

    The decision follows a recommendation by the Independent Data Monitoring Committee (IDMC) based upon successful completion of a pre-specified interim futility analysis after 80 progression-free survival (PFS) events as determined by blinded, independent central review. ImmunoGen has also completed full enrollment of the trial two months ahead of schedule and expects top-line results from FORWARD I during the first half of 2019. “Ovarian cancer is the leading cause of death from gynecological cancers, and patients diagnosed with this life-threatening disease have limited treatment options, especially once they develop platinum-resistant disease,” said Anna Berkenblit, M.D., vice president and chief medical officer of ImmunoGen.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes